Revolution Medicines (RVMD) Q3 FY25 earnings call

Earnings call· Sep 2025 (Q3 FY25)· Health Care· Nov 5, 2025

Source: earnings call transcript

Revolution Medicines continues to advance its RAS(ON) inhibitor portfolio, making substantial clinical progress with daraxonrasib in pancreatic and lung cancers, and elironrasib in NSCLC. The company is expanding its pipeline with new trials and a G12V-selective inhibitor, supported by a strong financial position and strategic organizational scaling for global commercialization.

You’re reading a preview. Opening the full call uses 1 concall credit.

Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.